Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Pharmacol Res. 2017 Feb 14;119:242–250. doi: 10.1016/j.phrs.2017.02.013

Figure 5.

Figure 5

Combinatory therapy with BRAFi+MEKi+2ME induced cell proliferation inhibition and increase of cell death in naïve SK-Mel-28 melanoma cells. (A) Absolute number of cells after treatment with BRAFi (250nM), MEKi (2.5nM) and/or 2ME (500nM) for 72h. (B) Cell viability proportion normalized to 100% for each condition after treatment with BRAFi (250nM), MEKi (2.5nM) and/or 2ME (500nM) for 72h. Experiments were performed in triplicates. Values are expressed as mean ± s.d. Significance is indicated by *P<0.05, **P<0.01 and ***P<0.001.